{"protocolSection":{"identificationModule":{"nctId":"NCT04649632","orgStudyIdInfo":{"id":"CLIN-52120-450"},"organization":{"fullName":"Ipsen","class":"INDUSTRY"},"briefTitle":"Relation Between Dose and Time to Reinjection of Botulinum Toxin-A in Patient With Poststroke Spasticity From a Real-world Healthcare Insurance Database.","officialTitle":"Relation Between Dose and Time to Reinjection of Botulinum Toxin-A in Patient With Poststroke Spasticity From a Real-world Healthcare Insurance Database.","acronym":"Relax"},"statusModule":{"statusVerifiedDate":"2020-11","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2020-04-29","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2020-09-18","type":"ACTUAL"},"completionDateStruct":{"date":"2020-09-18","type":"ACTUAL"},"studyFirstSubmitDate":"2020-11-12","studyFirstSubmitQcDate":"2020-11-25","studyFirstPostDateStruct":{"date":"2020-12-02","type":"ACTUAL"},"lastUpdateSubmitDate":"2020-11-25","lastUpdatePostDateStruct":{"date":"2020-12-02","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Ipsen","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":false},"descriptionModule":{"briefSummary":"Determining the mean/median time between botulinum toxin-A injection within the treatment of patients with spasticity after stroke in relation to the botulinum toxin dose from a healthcare insurance database in the Netherlands."},"conditionsModule":{"conditions":["Post Stroke Spasticity"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"RETROSPECTIVE"},"enrollmentInfo":{"count":451,"type":"ACTUAL"}},"outcomesModule":{"primaryOutcomes":[{"measure":"Mean time to next injection per brand","timeFrame":"From baseline up to end of data collection (January 2012 up to December 2016)"},{"measure":"Median time to next injection per brand","timeFrame":"From baseline up to end of data collection (January 2012 up to December 2016)"},{"measure":"Dosing of botulinum toxin-A in daily practice in relation to time to next injection","timeFrame":"From baseline up to end of data collection (January 2012 up to December 2016)"}],"secondaryOutcomes":[{"measure":"Average cost per year per brand per patient","timeFrame":"From baseline up to end of data collection (January 2012 up to December 2016)"},{"measure":"Exploring factors like age, gender, time since diagnosis stroke that influence dosing and time between botulinum toxin-A treatments","timeFrame":"From baseline up to end of data collection (January 2012 up to December 2016)"},{"measure":"Time interval between 2 injections of the same brand","timeFrame":"From baseline up to end of data collection (January 2012 up to December 2016)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* A patient will be included if he has a diagnosis stroke within the rehabilitation setting and has received at least two injections of botulinum toxin-A: Dysport or Botox\n\nExclusion Criteria:\n\n* A patient will be excluded if he has been only treated with Xeomin","healthyVolunteers":false,"sex":"ALL","minimumAge":"25 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"All patients selected from the database claimed within the code 313 will be included in the descriptive analyses.","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"overallOfficials":[{"name":"Ipsen Medical Director","affiliation":"Ipsen","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Ipsen Facility","city":"Hoofddorp","zip":"2132LS","country":"Netherlands","geoPoint":{"lat":52.3025,"lon":4.68889}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000009128","term":"Muscle Spasticity"}],"ancestors":[{"id":"D000009135","term":"Muscular Diseases"},{"id":"D000009140","term":"Musculoskeletal Diseases"},{"id":"D000009122","term":"Muscle Hypertonia"},{"id":"D000020879","term":"Neuromuscular Manifestations"},{"id":"D000009461","term":"Neurologic Manifestations"},{"id":"D000009422","term":"Nervous System Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M11775","name":"Muscle Spasticity","asFound":"Spasticity","relevance":"HIGH"},{"id":"M11782","name":"Muscular Diseases","relevance":"LOW"},{"id":"M11787","name":"Musculoskeletal Diseases","relevance":"LOW"},{"id":"M11769","name":"Muscle Hypertonia","relevance":"LOW"},{"id":"M22309","name":"Neuromuscular Manifestations","relevance":"LOW"},{"id":"M12094","name":"Neurologic Manifestations","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC05","name":"Musculoskeletal Diseases"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M4873","name":"Botulinum Toxins","relevance":"LOW"},{"id":"M250157","name":"abobotulinumtoxinA","relevance":"LOW"},{"id":"M20947","name":"Botulinum Toxins, Type A","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}